Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS opened at $0.03 on Monday. The company has a 50-day moving average of $0.03 and a 200-day moving average of $0.04. The company has a market capitalization of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.81.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.